Effects of glipizide and metformin on serum insulin-like growth factor-1, 2 in patients with type Ⅱ diabetes mellitus

Abstract

Abstract: Aim To study the effects of glipizide and meh formin on the serum IGF-1, IGF-2 in patients with type II diabetes mellitus; Methods The effect of glipizide (n =40) and metformin(n =25) on serum IGF-1, IGF-2 in patients with type I diabetes mellitus were compared with self-controlled study. Results In metformin treated patients, there were not significantly changes in fasting IGF-1 and IGF-2 concentrations In glipizide-treated patients there were markedly increased IGF-1 concentrations (181 8±104.5) vs (209.0 ±88.2)ng·ml^-1(P<0.05) while serum IGF-2 was not change. There was a significant reduction of blood glucose in two groups at the end of treatment (both P <3.01) but C-peptide level was markedly increased(P <0.05) only in glipizi detreated patients. Conclusion The changes of IGF-1 is markedly different between metformin-treated and glipizide-treated patients with type II diabetes mellitus.

Key words: insulin-like growth factor, type H diabetes mellitus, glipizide, metformin

CLC Number:

R969.1

PEI Jian-Hao, YANG Hua-Zhang, KUANG Jian, LIAO Xiao-Zhen, CHENG Chong, CHENG Hong, LI Zhong-Wen, CUI Yan. Effects of glipizide and metformin on serum insulin-like growth factor-1, 2 in patients with type Ⅱ diabetes mellitus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2001, 6(1): 38-40.

References

1 Sara VR, Hall K. Insulin-like growth factor and their binding proteins. Physiol Rev, 1990; 70: 591
2 Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res, 1994; 42: 140
3 Zapf J. Physiological role of the insulin "like growth factor binding proteins. Eur J Endocrinol, 1996; 132: 645
4 Goke B. Insulin and the insulin-like growth factor-1: their role as risk factors in the development of diabetic cardiovascular disease. Diabetes Res Clin Pract, 1996; 30: 93
5 廖二元, 许樟荣.SS/GHRH-GH-IGF-1轴与糖尿病.中国糖尿病杂志, 1996; 4: 110
6 Bach LA, Rechler MM. Insulin-like growth factors and diabetes. Diabetes/M etabolism Reviews, 1992; 8: 229
7 Rajaram SJ, Baylink DJ, Moham S, et al. Insulin-like growth factor binding proteins in serum and other biological fluids: regulation and function. Endocrinol Rev, 1997; 18: 801
8 Gibson JM,Westwood M, Crosby SR, et al. Choice of treatment affects plasma levels of insuin-growth factor-binding protein-1 in noninsulin dependent diabetes mellitus. J Clin Endocrinol Metab,1995; 80: 1369
9 Gibson JM. Redued insuin-growth factor binding pro- tein-KIGFBP-1)levels correlate with increased cardiovascular risk in noninsulin dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab, 1996; 81: 860
10 萧新华, 王洹.胰岛素生长因子与I 型糖尿病.世界医学, 1997; 1:50
11 Oscarsson J, Conover CA, Lee PDK, et al. Recombinant hum an insulin-like growth factor-1 decreases serum lipoprotein (a) concentrations in normal adult men. Clin Endocrinol Oxf, 1995; 42: 6 73
12 Zenobi PD,Holzmann P, Glatz Y,et al. Improvement of lipid profile in type 2 (non-insulin-dependen) diabetes mellitus by insulin-like growth factor-1. Dia-betologia, 1993; 36: 465
13 Schalch DS, Turman NJ, Crosby SR, e t al. Shortterm effects of recombinant human insulin-like growth factor-1 on metabolic control of patients with type II diabetes mellitus. J Clin Endocrinol Metab, 1993; 77: 1563
14 Prewitt TE, Unterman TG, Glick R, et al. Insulin-like growthfactor-1 and low density lipoprotein cholesterol in women during high and low-fat feed. Am J Clin-Nutr, 1992; 55: 3 81
15 Hoogerbrugge V, linden N, Jansen H,e t al. Relation ship between insulin-like growth factor-1 and low density lipoprotein cholesterol levels in prim ary hypothyroidism in women. Endocrinol,1989; 123: 341
16 Ostlund Jr RE, Staten MA, Kohrt WM, et a l. Insulin-like growth factor and apolipoprotein B. JAMA, 1992; 126: 1937

[1]	WANG Jie, LI Long, CHEN Feng, LIU Shengfei. Research progress of metformin in the pathogenesis of pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 235-240.
[2]	WANG Xin, LIU Weiying, WU Chen, KAI Jinjun, LIANG Xuejie, CHANG Yingxuan. Metformin regulates AMPK/SREBP-1 pathway and its clinical application [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1049-1054.
[3]	WANG Zhen, QUAN Haiyan, HONG Chenliang, YUAN Lijialong, QIN Xuping. Swimming improves renal function of diabetic mice by promoting autophagy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 632-638.
[4]	HAO Wei, ZUO Dongze, ZHANG Junxiu, JIANG Lili, XIONG Ying, YANG Jieren. Effects of metformin on epithelial-mesenchymal transition of rat alveolar epithelial type II cells induced by TGF-β1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 744-752.
[5]	LI Xiaomin, JIN Hao, ZHOU Wenzhi, YANG Hanyue, ZOU Ting, GUO Jie, XU Pingsheng. Bioequivalence of metformin hydrochloride sustained-release tablets in healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 408-413.
[6]	LI Guinv, REN Shaolin, SHEN Ruiming, JI Yongneng, CAI Cairong, SU Ruo. Metformin combined with glucocorticoid in the treatment of SLE patients with IGT [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 670-676.
[7]	GUO Liangtang, LIN Chao, SUN Yun, DAI Shengfeng, ZHANG Bingcai, CHEN Shu. Effects of metformin on patients with polycystic ovary syndrome and its effect on adipose tissue miR-25 level [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 554-560.
[8]	DING Qiuhua, SHI Daohua. Advances on the molecular mechanism of metformin's antitumor effect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 350-354.
[9]	CHEN Yan, ZHU Lijun, FANG Zhengmei, ZHU Hui, JIN Yuelong, SHEN Chong, YAO Yingshui. Association of insulin-like growth factor(IGF)-1 polymorphisms and efficacy of antihypertensive drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 171-179.
[10]	YAO Xinming, KONG Xiang, ZHAO Yongli, HUA Qiang, HE Chunling, YU Dan, LI Yeqiong, DAI Xiaokang, YE Shandong. Metformin inhibits p38MAPK signaling pathway and oxidativestress in rat glomerular mesangial cells cultured with high glucose [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 614-620.
[11]	SHI Dejun, LIU Yi. Effects of different doses of metformin on bone metabolism and bone mineral density in elderly male patients with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1045-1049.
[12]	WEI You-quan, CAO Heng. Effects of recombinant human insulin-like growth factor-Ι on the expression of matrix metalloproteinases and interstitial degradation of myocardial infarction rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 866-871.
[13]	QIAN Su-bo, CHEN Mu, SHEN Hai-bo, QI Jun. Effects of shRNA targeting IGF2 gene on the growth and cell cycle of human bladder cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1233-1237.
[14]	RUAN Guan-yu, XU Qiu-xing, CAI Hui-ya, DENG Jie, SHI Dao-hua. Comparison of neonatal outcomes in women with gestational diabetes mellitus treated with metformin or insulin: a systematic review [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1139-1143.
[15]	ZHEN Dong-hu, LIU Li-juan, CHEN Jian-guo, TANG Xu-lei. Effects of metformin on intracellular reactive oxygen species and apoptosis induced by advanced glycation end products on rat cranioaural osteoblasts [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 743-748.